Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Ketamine vs Midazolam for OCD
NCT02206776Phase 2Terminated
- Sponsor
- New York State Psychiatric Institute
- Start
- Sep 2014
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ketamine in obsessive compulsive disorder (OCD) (2 arms), sponsored by New York State Psychiatric Institute. Primary endpoint: Number of Patients Who Met and Exceeded Response Criteria of Yale-Brown Obsessive-Compulsive Scale at 1 week. Started Sep 2014; status: terminated.
02
Drugs
ketamine
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on NCT02206776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02206776.